Women taking pill may be less likely to suffer ACL injury, study finds

The Guardian,

SHINE SA Media Release: Response to the call to ban Diane-35

SHINE SA, issued 13th December 2017

SHINE SA believes everyone should have access to contraceptive choices, and that decisions about contraception are best made in conjunction with a healthcare professional.

Cyproterone acetate pills, commonly known as Diane-35 appear to be associated with a higher risk of deep venous thrombosis (DVT) than levonorgestrel (LNG) containing pills, although the overall risk is still very low for most people.

For those who choose combined pills, we recommend as first choice the pills with lowest risk: those containing levonorgestrel or norethisterone as their progesterone. However, the other progestogen choices, which all carry a small increased risk of DVT compared to LNG, may be utilised if specific added benefits are required. Health professionals can review over time the experience individuals may have with their contraceptive choice.

Cyproterone acetate can be used as treatment for signs of androgenisation in people such as severe acne (involving inflammation or nodularity, or risk of scarring) where prolonged oral antibiotics or local treatment alone have not been successful, or idiopathic hirsutism of mild to moderate degree. The oral contraceptive pill containing cyproterone acetate can also provide effective oral contraception in this patient group.
People who have concerns should seek advice from their doctor before stopping their oral contraceptive pill.

Download Media release (PDF): Response to the call to ban Diane-35 SHINE SA Diane35_13 Dec 17_FS

 

Rescheduling of ulipristal acetate (EllaOne®) in Australia

SHine SA, October 2016

SHine SA and Family Planning Alliance Australia put in submissions to the TGA for the rescheduling of ulipristal acetate (EllaOne®), a new emergency contraceptive pill in Australia.

The rescheduling is from prescription-only to Schedule 3 (available in pharmacies with a pharmacy consultation). This has now been approved, to take place from February 2017.

This is an important access issue.

EllaOne® emergency contraception has also been added to the SHine SA formulary.

Access TGA information about ulipristal acetate (including links to the public submissions) here 

Window of vulnerability for STIs to infect human female reproductive tract

Science Daily, March 16, 2015

A comprehensive review of the role of sex hormones in the geography of the female reproductive tract has been presented by researchers, with evidence supporting a “window of vulnerability” to HIV and other sexually transmitted infections (STIs).

Read more here

Oral contraceptive use and mortality

ABC Health Report, Monday 2 February 2015 5:53PM

Researchers from Boston have followed 120,000 female nurses for around 40 years, looking at their health and wellbeing, including their contraception and comparing that to cause and age at death. They wanted to find out whether oral contraceptive use is associated with total and cause specific mortality.